Loading clinical trials...
Loading clinical trials...
Study to Assess the Feasibility of GSK Bio's Candidate HBV / MPL Vaccines Following Different Schedules and Formulations and to Compare Their Safety and Immunogenicity to That of Engerix™-B in Healthy Adolescents Aged 11 to 15
Conditions
Interventions
HBV-MPL vaccine Formulation A
HBV-MPL vaccine Formulation B
+1 more
Locations
1
Germany
GSK Clinical Trials Call Center
Mainz, Germany
Start Date
March 1, 1998
Primary Completion Date
May 1, 1999
Last Updated
June 16, 2008
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions